← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksHRMYRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Harmony Biosciences Holdings, Inc. (HRMY) Revenue History

Annual and quarterly revenue from 2018 to 2025

TTM Revenue
$868.5M
vs. $714.7M LY
YoY Growth
+21.1%
Excellent
Latest Quarter
$243.8M
Q4 2025
QoQ Growth
+1.8%
Slow

Compound Annual Growth Rate (CAGR)

3-Year+25.6%Excellent
5-Year+40.3%Excellent
10-Year-
Highest Annual Revenue$868.5M (2025)
Highest Quarter$243.8M (Q4 2025)
Revenue per Share$14.83

Loading revenue history...

Revenue Growth Metrics

1-Year Growth
+21.1%
Excellent
3-Year CAGR
+25.6%
Excellent
5-Year CAGR
+40.3%
Excellent
10-Year CAGR
-
TTM vs Prior Year+$153.7M (+21.5%)
Revenue per Share$14.83
Peak Annual Revenue$868.5M (2025)

Revenue Breakdown

HRMY's revenue distribution by segment and geography

By Geography

United States100.0%

Download Historical Data

8 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

HRMY Revenue Analysis (2018–2025)

As of March 1, 2026, Harmony Biosciences Holdings, Inc. (HRMY) generated trailing twelve-month (TTM) revenue of $868.5 million, reflecting exceptional growth of +21.1% year-over-year. The most recent quarter (Q4 2025) recorded $243.8 million in revenue, up 1.8% sequentially.

Looking at the longer-term picture, HRMY's 5-year compound annual growth rate (CAGR) stands at +40.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $868.5 million in 2025, representing a new all-time high.

When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), HRMY has underperformed the peer group in terms of revenue growth. Compare HRMY vs AGIO →

Peer Comparison

Compare HRMY's revenue metrics with industry peers

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
HRMYCurrent$868M+21.1%+40.3%24.0%
AGIO$54M+36.3%--873.9%
VRTX$12.0B+10.4%+14.1%39.1%
ASND$692M+97.4%+150.9%-18.9%
BBIO$502M+126.3%+127.4%-113.3%
BMRN$3.2B+12.9%-16.6%
Best in groupLowest in group

Historical Revenue Data

Showing 8 of 8 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$868.5M+21.5%$670.1M77.2%$208.5M24.0%
2024$714.7M+22.8%$557.9M78.1%$190.8M26.7%
2023$582.0M+32.9%$460.8M79.2%$192.0M33.0%
2022$437.9M+43.4%$354.4M80.9%$120.2M27.4%
2021$305.4M+91.2%$249.9M81.8%$87.5M28.7%
2020$159.7M+2564.6%$132.0M82.6%$17.0M10.6%
2019$6.0M-$4.4M73.7%$-145,904,000-2433.8%
2018$0-$-184,000-$-41,439,000-

See HRMY's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is HRMY Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare HRMY vs AGIO

See how HRMY stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

Is HRMY's revenue growth accelerating or slowing?

HRMY revenue is accelerating at +21.1% year-over-year, exceeding the 5-year CAGR of +40.3%. TTM revenue reached $868M. Growth momentum has increased versus prior periods.

What is HRMY's long-term revenue growth rate?

Harmony Biosciences Holdings, Inc.'s 5-year revenue CAGR of +40.3% reflects the sustained expansion pattern. Current YoY growth of +21.1% is above this long-term average.

How is HRMY's revenue distributed by segment?

HRMY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.

Revenue Over Time